Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.

NCT01552018 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT01552018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01552018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.
Lead sponsor
Oslo University Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2012
Completion date
February 28, 2014
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, diabetes mellitus type 2